Please assess the completion status of the following clinical trial:

Trial Title: Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected growth hormone deficiency (GHD), based on either of the following:~  * structural hypothalamic or pituitary disease, or~ * surgery or irradiation in these areas, or~ * head trauma as an adult, or~ * evidence of other pituitary hormone deficiencies, or~ * idiopathic childhood onset GHD (without known hypothalamic or pituitary lesion or injury).~* Healthy\* control subjects, matching a 'high likelihood GHD' subjects~Exclusion Criteria:~* GH therapy within 1 month prior to anticipated first GHST within this trial (within 3 months in case of long-acting GH formulation).~* GHST within 7 days prior to the anticipated first test day within the trial.~* Subjects with a medical history and clinical signs of a not adequately treated thyroid dysfunction or subjects who had a change in thyroid therapy within 30 days prior to anticipated first test day within the trial.~* Untreated hypogonadism or not on a stable substitution treatment within 30 days prior to anticipated first test day within the trial.~* Treatment with drugs directly affecting the pituitary secretion of somatotropin (e.g. somatostatin analogues, clonidine, levodopa, and dopamine agonists) or provoking the release of somatostatin; antimuscarinic agents (atropine).~* Concomitant use of a CYP3A4 inducer (e.g., carbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's Wort).~* Medical history of ongoing clinically symptomatic severe psychiatric disorders.~* Parkinson's disease.~* Cushing disease or patients on supraphysiologic glucocorticoid therapy within 30 days prior to the anticipated first test day within the trial.~* Type 1 diabetes or untreated or poorly controlled Type 2 diabetes, as defined by HbA1c \> 8%.~* Body mass index (BMI) ≥ 40.0 kg/m2.~* Participation in a trial with any investigational drug within 30 days prior to trial entry.~* Vigorous physical exercise within 24 hours prior to each GHST within this trial.~* Known hypersensitivity to macimorelin or insulin, or any of the constituents of either preparation.~* Clinically significant cardiovascular or cerebrovascular disease.~* Prolonged ECG QT interval, defined as corrected QT interval (QTc) \> 500 msec.~* Concomitant treatment with any drugs that might prolong QT/QTc.~* Elevation of laboratory parameters indicating hepatic or renal dysfunction or damage (aspartate amino transferase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyl transpeptidase (GGT)\> 2.5 x ULN; ), creatinine, or bilirubin \> 1.5x ULN).~* Medical history of seizure disorders.~* Known immunosuppression.~* Current active malignancy other than non-melanoma skin cancer.~* Breastfeeding or positive urine pregnancy test (for women of childbearing potential only).~* Women of childbearing age without contraception, such as hormonal contraception or use of condom and spermicides or use of diaphragm and spermicides or Intra Uterine Device (IUD).~* Lack of ability or willingness to give informed consent.~* Anticipated non-availability for trial visits/procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- GHST Sequence A (Type: EXPERIMENTAL): 1st Macimorelin-GHST, 2nd Insulin Tolerance Test
- GHST Sequence B (Type: EXPERIMENTAL): 1st Insulin Tolerance Test, 2nd Macimorelin-GHST

Based on this trial design, predict the completion outcome and termination type (if applicable).